Midwest Neurology Associates PC

Midwest Neurology Associates PC was paid $2.42M by Medicaid between Jan 2018 and Dec 2024, across 63 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 49% of everything it billed.

33Billing provider infoMIDWEST NEUROLOGY ASSOCIATES PC
DYER, IN 46311

33aNPI1124453279assigned 09/09/2013

33bProvider typeNeurology Physician

28Total paid$2.42M

24GClaims51,420

24DCodes billed63

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other Neurology Physician providers in Indiana

Rank by total paid#5 of 46

Median peer was paid$99K

This provider vs. median24×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	8,326	$114K
2019	5,502	$181K
2020	5,483	$243K
2021	7,811	$328K
2022	7,827	$464K
2023	9,728	$569K
2024incomplete	6,743	$518K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	49%	21,946	17,088	$1.19M
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	10%	2,572	2,201	$252K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	10.0%	6,171	4,928	$241K
95819		6.9%	835	682	$167K
95816		5.4%	588	555	$131K
J0585	Injection, onabotulinumtoxina, 1 unit	2.7%	371	158	$65K
95886		2.4%	545	394	$58K
95912		1.8%	332	243	$45K
95923		1.6%	486	360	$38K
99203	Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity	1.4%	471	425	$34K
64483		1.3%	244	185	$31K
76942		<1%	937	478	$21K

51 more codes

99215	Doctor's office visit, returning patient (complex)	<1%	1,024	$19K
J1040	Injection, methylprednisolone acetate, 80 mg	<1%	2,225	$15K
64493		<1%	195	$10K
95700		<1%	27	$9K
64615		<1%	222	$9K
64490		<1%	105	$9K
20552		<1%	412	$7K
99233	Hospital visit by a doctor, follow-up day (complex)	<1%	193	$7K
J1030	Injection, methylprednisolone acetate, 40 mg	<1%	1,880	$7K
95813		<1%	35	$6K
64484		<1%	137	$6K
64494		<1%	196	$5K
77002		<1%	804	$5K
62321		<1%	49	$5K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	836	$5K
64491		<1%	105	$4K
99223	Prolong inpt eval add15 m	<1%	42	$3K
99205	Prolong outpt/office vis	<1%	23	$3K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	107	$2K
97124		<1%	62	$2K
99152		<1%	121	$2K
20553		<1%	76	$1K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	180	$952.56
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	134	$719.35
80053	Comprehensive metabolic panel	<1%	154	$437.51
82607		<1%	141	$349.41
98960		<1%	27	$345.28
36415	Collection of venous blood by venipuncture	<1%	324	$342.90
20611		<1%	18	$341.65
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	51	$247.31
J3490	Unclassified drugs	<1%	57	$217.94
J3420	Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg	<1%	171	$70.51
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	<1%	540	$43.40
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	<1%	1,785	$37.90
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	13	$9.86
J0665	Injection, bupivicaine, not otherwise specified, 0.5 mg	<1%	48	$0.28
1160F		0%	2,131	$0.00
3288F		0%	126	$0.00
G8730	Pain assessment documented as positive using a standardized tool and a follow-up plan is documented	0%	148	$0.00
95951		0%	52	$0.00
1124F		0%	98	$0.00
G8427	Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications	0%	160	$0.00
G8417	Bmi is documented above normal parameters and a follow-up plan is documented	0%	124	$0.00
G9584	Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy	0%	61	$0.00
93272		0%	15	$0.00
84443	Thyroid stimulating hormone (TSH)	0%	12	$0.00
82728		0%	18	$0.00
85027		0%	26	$0.00
1036F		0%	45	$0.00
2010F		0%	371	$0.00
G8510	Screening for depression is documented as negative, a follow-up plan is not required	0%	16	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKASSAR, SAMER (OWNER)